Effects of tissue plasminogen activator and dual antiplatelet therapy in acute ischemic stroke treatment

Phase 2

Recruiting

• Conditions: acute ischemic stroke.; cerebrovascular (embolic) (ischemic) (thrombotic)

• Registration Number: IRCT2017082117756N24
• Lead Sponsor: Vice-chancellery of Research, Birjand University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 22 February 2018

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 60

Inclusion Criteria

Proved ischemic stroke; informed consent for participation; stroke symptoms initiated within 4.5 hours before admission; no brain hemorrhage on initial computerized tomography scan; clinical national institutes of health stroke scale between 4 and 18.
Exclusion criteria: Age 80 years or above; brain hemorrhage in initial computerized tomography scan; history of stroke; history of diabetes mellitus; patients currently receiving oral anticoagulant treatment without considering the international normalized ratio; clinical national institutes of health stroke scale above 25; large ischemic changes of brain or involvement of more than one-third of middle cerebral artery supplying zone in the initial computerized tomography scan.

Exclusion Criteria

Not provided

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
ational Institutes of Health Stroke Scale score. Timepoint: at the initial presentation, after 24 and 48 hours, and at discharge from hospital. Method of measurement: Physical examination.

Secondary Outcome Measures

Name	Time	Method
Complications of tissue plasminogen activator treatment. Timepoint: after 24 and 48 hours from the initiation of treatment and at discharge from hospital. Method of measurement: brain computerized tomography scan.